• Home
  • About
    • Overview
    • Sharing Data
    • ORCID
  • Help
  • History (1)
    • Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
    • See All Pages
  • search
    • Find People
    • Find Everything
Login to edit your profile (add a photo, awards, links to other websites, etc.)
  • Edit My Profile
  • My Person List (0)

Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.

Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response. Clin Cancer Res. 2019 02 01; 25(3):1036-1049.

View in: PubMed

subject areas
  • Animals
  • Antibodies
  • Biphenyl Compounds
  • Cell Line, Tumor
  • Humans
  • Immunotherapy, Adoptive
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Neoplasms, Experimental
  • Programmed Cell Death 1 Receptor
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-pim-1
  • Thiazolidines
  • T-Lymphocytes
  • Treatment Outcome
  • Xenograft Model Antitumor Assays

authors with profiles
  • Xuezhong Yu
  • Elizabeth G. Hill
  • Carsten Krieg
  • Meenal Mehrotra
  • Paramita Chakraborty
  • Craig Cano Beeson
  • Shikhar Mehrotra
  • Andrew S Kraft